The Leeds Teaching Hospitals NHS Trust, UK.
University of Liverpool, UK.
Ann R Coll Surg Engl. 2022 Sep;104(8):624-631. doi: 10.1308/rcsann.2021.0274. Epub 2022 Feb 8.
The COVID-19 pandemic resulted in a significant disruption of colorectal cancer (CRC) care pathways. This study evaluates the management and outcomes of patients with primary locally advanced or recurrent CRC during the pandemic in a single tertiary referral centre.
Patients undergoing elective surgery for advanced or recurrent CRC with curative intent between March 2020 and March 2021 were identified. Following first multidisciplinary team discussion patients were broadly classified into two groups: straight to surgery (=22, 45%) or neoadjuvant therapy followed by surgery (=27, 55%). Primary outcome was COVID-19-related complication rate.
Forty-nine patients with a median age of 66 years (interquartile range: 54-73) were included. No patients developed a COVID-19 infection or related complication during hospital admission. Significant delays were identified in the treatment pathway of patients in the straight to surgery group, mostly due to delays in referral from external centres. Nine of 22 patients in the straight to surgery group had evidence of tumour progression compared with 3 of 27 in the neoadjuvant group (=0.015839). Seven of 27 patients in the neoadjuvant group showed evidence of tumour regression. During the study, surgical waiting times were reduced, and more operations were performed during the second wave of COVID-19.
This study suggests that it is possible to mitigate the risks of COVID-19-related complications in patients undergoing complex surgery for locally advanced and recurrent CRC. Delay in surgical intervention is associated with tumour progression, particularly in patients who may not have neoadjuvant therapy. Efforts should be made to prioritise resources for patients requiring time-sensitive surgery for advanced and recurrent CRC.
COVID-19 大流行导致结直肠癌(CRC)治疗路径严重中断。本研究评估了在单一三级转诊中心中,大流行期间具有原发性局部晚期或复发性 CRC 的患者的管理和结局。
确定了 2020 年 3 月至 2021 年 3 月期间因有治愈意图的晚期或复发性 CRC 接受择期手术的患者。首次多学科团队讨论后,患者被广泛分为两组:直接手术组(=22,45%)或新辅助治疗后手术组(=27,55%)。主要结局是 COVID-19 相关并发症发生率。
共纳入 49 名中位年龄为 66 岁(四分位距:54-73)的患者。无患者在住院期间发生 COVID-19 感染或相关并发症。直接手术组患者的治疗路径存在明显延迟,主要是由于外部中心的转诊延迟。22 名直接手术组中有 9 名患者有肿瘤进展的证据,而新辅助组中有 3 名患者(=0.015839)。27 名新辅助组中有 7 名患者有肿瘤消退的证据。在研究期间,手术等待时间缩短,并且在 COVID-19 的第二波期间进行了更多的手术。
本研究表明,对于接受局部晚期和复发性 CRC 复杂手术的患者,有可能减轻 COVID-19 相关并发症的风险。手术干预的延迟与肿瘤进展相关,特别是在可能不需要新辅助治疗的患者中。应努力为需要接受时间敏感型手术的晚期和复发性 CRC 患者分配资源。